Delgocitinib in the Treatment of Chronic Hand Eczema: a Clinical and Pharmacological Analysis of a First-in-Class Targeted Therapy
Delgocitinib, primo inibitore pan-JAK approvato per l'eczema cronico delle mani (Chronic Hand Eczema, CHE) segna un cambio di paradigma terapeutico nella gestione di una patologia storicamente gravata da un significativo unmet medical need. Questa tesi analizza il profilo farmacologico e clinico del farmaco e i dati di sicurezza ed efficacia emersi dai trials clinici registrativi (DELTA1 e DELTA2). Delgocitinib si configura come pilastro di una strategia terapeutica personalizzata capace di superare i limiti delle terapie convenzionali per CHE.
Delgocitinib, the first pan-JAK inhibitor approved for the treatment of Chronic Hand Eczema (CHE), represents a paradigm shift in the management of a disease historically burdened by a significant unmet medical need. This thesis analyzes the pharmacological and clinical profile of the drug, as well as the efficacy and safety data emerging from the pivotal registrational clinical trials (DELTA1 and DELTA2). Delgocitinib emerges as a cornerstone of a personalized therapeutic strategy capable of overcoming the limitations of conventional treatments for CHE.